Best of the Week
Most Popular
1. Investing in a Bubble Mania Stock Market Trending Towards Financial Crisis 2.0 CRASH! - 9th Sep 21
2.Tech Stocks Bubble Valuations 2000 vs 2021 - 25th Sep 21
3.Stock Market FOMO Going into Crash Season - 8th Oct 21
4.Stock Market FOMO Hits September Brick Wall - Evergrande China's Lehman's Moment - 22nd Sep 21
5.Crypto Bubble BURSTS! BTC, ETH, XRP CRASH! NiceHash Seizes Funds on Account Halting ALL Withdrawals! - 19th May 21
6.How to Protect Your Self From a Stock Market CRASH / Bear Market? - 14th Oct 21
7.AI Stocks Portfolio Buying and Selling Levels Going Into Market Correction - 11th Oct 21
8.Why Silver Price Could Crash by 20%! - 5th Oct 21
9.Powell: Inflation Might Not Be Transitory, After All - 3rd Oct 21
10.Global Stock Markets Topped 60 Days Before the US Stocks Peaked - 23rd Sep 21
Last 7 days
Chinese Tech Stocks CCP Paranoia and Best AI Tech Stocks ETF - 26th Oct 21
Food Prices & Farm Inputs Getting Hard to Stomach - 26th Oct 21
Has Zillow’s Collapse Signaled A Warning For The Capital Markets? - 26th Oct 21
Dave Antrobus Welcomes Caribou to Award-Winning Group Inc & Co - 26th Oct 21
Stock Market New Intermediate uptrend - 26th Oct 21
Investing in Crypto Currencies With Both Eyes WIDE OPEN! - 25th Oct 21
Is Bitcoin a Better Inflation Hedge Than Gold? - 25th Oct 21
S&P 500 Stirs the Gold Pot - 25th Oct 21
Stock Market Against Bond Market Odds - 25th Oct 21
Inflation Consequences for the Stock Market, FED Balance Sheet - 24th Oct 21
To Be or Not to Be: How the Evergrande Crisis Can Affect Gold Price - 24th Oct 21
During a Market Mania, "no prudent professional is perceived to add value" - 24th Oct 21
Stock Market S&P500 Rallies Above $4400 – May Attempt To Advance To $4750~$4800 - 24th Oct 21
Inflation and the Crazy Crypto Markets - 23rd Oct 21
Easy PC Upgrades with Motherboard Combos - Overclockers UK Unboxing - MB, Memory and Ryzen 5600x CPU - 23rd Oct 21
Gold Mining Stocks Q3 2021 - 23rd Oct 21
Gold calmly continues cobbling its Handle, Miners lay in wait - 23rd Oct 21
US Economy Has Been in an Economic Depression Since 2008 - 22nd Oct 21
Extreme Ratios Point to Gold and Silver Price Readjustments - 22nd Oct 21
Bitcoin $100K or Ethereum $10K—which happens first? - 22nd Oct 21
This Isn’t Sci-Fi: How AI Is About To Disrupt This $11 Trillion Industry - 22nd Oct 21
Ravencoin RVN About to EXPLODE to NEW HIGHS! Last Chance to Buy Before it goes to the MOON! - 21st Oct 21
Stock Market Animal Spirits Returning - 21st Oct 21
Inflation Advances, and So Does Gold — Except That It Doesn’t - 21st Oct 21
Why A.I. Is About To Trigger The Next Great Medical Breakthrough - 21st Oct 21
Gold Price Slowly Going Nowhere - 20th Oct 21
Shocking Numbers Show Government Crowding Out Real Economy - 20th Oct 21
Crude Oil Is in the Fast Lane, But Where Is It Going? - 20th Oct 21
3 Tech Stocks That Could Change The World - 20th Oct 21
Best AI Tech Stocks ETF and Investment Trusts - 19th Oct 21
Gold Mining Stocks: Will Investors Dump the Laggards? - 19th Oct 21
The Most Exciting Medical Breakthrough Of The Decade? - 19th Oct 21
Prices Rising as New Dangers Point to Hard Assets - 19th Oct 21
It’s not just Copper; GYX indicated cyclical the whole time - 19th Oct 21
Chinese Tech Stocks CCP Paranoia, VIES - Variable Interest Entities - 19th Oct 21
Inflation Peaked Again, Right? - 19th Oct 21
Gold Stocks Bouncing Hard - 19th Oct 21
Stock Market New Intermediate Bottom Forming? - 19th Oct 21
Beware, Gold Bulls — That’s the Beginning of the End - 18th Oct 21
Gold Price Flag Suggests A Big Rally May Start Soon - 18th Oct 21
Inflation Or Deflation – End Result Is Still Depression - 18th Oct 21
A.I. Breakthrough Could Disrupt the $11 Trillion Medical Sector - 18th Oct 21
US Economy and Stock Market Addicted to Deficit Spending - 17th Oct 21
The Gold Price And Inflation - 17th Oct 21
Went Long the Crude Oil? Beware of the Headwinds Ahead… - 17th Oct 21
Watch These Next-gen Cloud Computing Stocks - 17th Oct 21
Overclockers UK Custom Built PC 1 YEAR Use Review Verdict - Does it Still Work? - 16th Oct 21
Altonville Mine Tours Maze at Alton Towers Scarefest 2021 - 16th Oct 21

Market Oracle FREE Newsletter

How to Protect your Wealth by Investing in AI Tech Stocks

The Seven Financial Indicators of Highly Successful Biotech Stocks Investing

Companies / BioTech Feb 21, 2015 - 10:41 AM GMT

By: Money_Morning

Companies

Ernie Tremblay writes: When evaluating biotech stocks, many key indicators that work for other industries – e.g. price-to-earnings ratio, profit margin, revenue-per-share – often don't apply.

Here's why they don't, and why seven of these critical financial indicators do…


The Usual Ratios Don't Apply

The reason is pretty straightforward: many low- and mid-cap biotechs haven't yet made a profit, and probably won't for years to come.

Unlike big pharmaceutical companies, these smaller startups focus their time, money, and effort on research and development, rather than marketing new products.

In fact, many of them don't maintain a sales force and have no intention of building one. Instead, they rely on business partnerships with companies that do concentrate on selling products to get their medications into the hands of doctors and hospitals.

For income, they rely on royalties, milestone payments, and public offerings of common stock.

Even those firms that do market their own products can go many years before seeing their first experimental drug approved, so thinking of valuation and potential in terms of profits won't take you very far.

Generally speaking, when assessing a biotech, the first thing an investor should look at is the company's drug pipeline. What great new medications is it developing to fill serious medical needs?

After that, however, there are some technical financial indicators – seven to be exact – that will prove very helpful in sizing up a stock before you buy it.

The Key Indicators

1) Burn Rate

This refers to the rate at which a company spends money versus its income. Ideally, you'd like a company to have enough cash on hand to operate for the next 13 to 18 months without having to raise money through a dilutive public offering.

The calculation is simple:

Burn rate = Capital expenditures + Negative cash flow from operating activities

You can retrieve these numbers from Yahoo Finance for any publicly traded stock. To get a more accurate picture of the financial road ahead, find these numbers for the most recent quarter and then divide the answer by three to estimate burn per month.

Next, calculate how much money the company has in its coffers:

Cash on hand = Cash and cash equivalents + Short-term investments

Finally, calculate the amount of time, in months, the company can continue to operate with current available funds:

Operation coverage = Available funds/monthly cash burn rate

2) Convertible Debt

Startup companies often use convertible debt to finance their operations. This simply means that the company borrows money from a lender and issues warrants to cover the debt. A warrant is a promise (bond) that gives the lender the right to purchase stock, often at a highly discounted, predetermined rate (strike price), in the future.

Using convertible debt is a perfectly legitimate way for a robust, larger, profitable company to raise financing, but for a fragile, small-cap, pre-profit biotech, not so much.

The problem is that lenders can – and often will – borrow shares and sell them short when a catalyst, such as an FDA approval, is driving share price rapidly upward, then cover (repurchase the shares) at a dirt cheap price by exercising their warrants. This is called convertible arbitrage.

If they do this with a sizable block of shares, the transactions can force the stock price to reverse direction, that is, sink when it should be rising.

To make matters worse, shares the lender purchases through warrants must be newly issued by the biotech, which has a dilutive effect, driving price down even more.

So your best bet is to look for biotechs with low or no warrants outstanding. This information isn't always obvious when looking over a balance sheet, but you can find it in their most recent 10-Q SEC filing, generally available on the company's website. Open the document and do a search on "contingent warrant liabilities."

3) Market Cap

Market capitalization is the total sum value of a company's outstanding shares, based on current price-per-share (PPS). This number can give you a couple of valuable hints about the attractiveness of a particular stock.

If the cap is very small, below about $250 million, the PPS can be extremely volatile on very low trading volume, so liquidity may be a problem-you can find yourself needing to sell with no one there to buy.

At the other extreme, if the cap is over $5 billion, the company may have reached the limits of its growth, unless it's developing a broad spectrum product portfolio that could help it become a full-fledged pharmaceutical company.

4) Volume/Average Volume

Like market cap, these numbers can help you decide if shares are liquid enough to allow you a quick exit, should you need to make one. Stocks that trade on average about 350,000 shares per day are a good bet. Fewer than 300,000 is getting into dicey territory. Under 200,000 is the Wild West.

You can also use volume to gauge investor sentiment – an important factor when trading stocks in an industry as volatile as biotech. A PPS downturn in lower than average volume probably indicates the stock's movement has little importance and does not indicate a trend.

The same price movement in high volume, however, can mean that institutions are bailing out, so it may be time to take the hint and follow their lead. The same principles apply to upward stock movement.

5) Beta

This measurement expresses how volatile a given stock is likely to be in comparison with the market, based on past performance. A Beta of 1 means equivalence with market volatility, while a number greater than 1 (e.g. 1.2, etc.) indicates higher volatility and less than 1 (e.g. 0.8, etc.) points to lower.

This number can give you some perspective on days when the stock market seems calm but one of your positions is jumping higher or lower for no apparent reason.

It can also help you buy stocks that fit your trading style. If you're a day trader, for example, you may want to get into stocks that can move significantly within a single session. Longer-term traders, however, might find stocks that move more gradually, along with the market, more attractive.

6) Short Interest

Short selling, as you probably know, is an investment tactic that can make money for a trader when a stock's value decreases. A short seller borrows shares from another shareholder, sells them, and then buys them back when the price goes lower, pocketing the difference.

An increase in short interest (expressed as short percentage of the float) can indicate a trend in market sentiment away from the stock, while a decrease in short interest can mean more confidence in the company's prospects.

If that were all there was to the story, short interest might be just an interesting risk indicator of where other investors feel the stock is going to go.

Unfortunately, the story doesn't stop there – the plot grows more sinister.

Because biotech stocks tend to be relatively inexpensive and trade in fairly low volume – especially in after-hours trading – they're vulnerable to price manipulation. And it happens.

It doesn't take much for a few hedge funds to sell large blocks of shares short, driving down price and creating negative momentum that scares longs into selling as well. At the same time, it's not uncommon to see anonymous campaigns to devalue a stock by disseminating false or misleading information about the issuing company through blogs, articles, and message boards.

This can happen even in the face of a strong positive catalyst, such as an FDA approval.

So a large percentage of short interest can indicate that fund managers are getting ready to force a particular company's PPS down, even if it has developed good new medications for sick and dying patients, all in the interest of short-term profits.

The question, then, is what represents a "large" percentage?

Although there are other factors to consider, in general, look for stocks with a short interest of less than 20%.

7) Bollinger Bands

Bollinger bands are a volatility indicator that can graphically show you a stock's standard deviations from a simple moving average over time. Go to the stock's Yahoo Finance page, bring up its chart, click on the Indicator button, and click Bollinger Bands in the dropdown menu.

This will bring up an upper and lower line that describe the stock's high and low volatility range. If the stock price touches or crosses either line more than once in a short period of time, it may be time to trade.

Touching the upper line repeatedly indicates the stock is probably overbought and may be headed downward soon – time to sell.

Touching the lower line repeatedly tells you the stock is oversold and should head upward – time to buy.

If a stock crosses over one of the lines and remains there for a few days, it's mostly likely consolidating at new high or low level.

A Final Word

None of these indicators will yield, by itself, a thumbs up or down for any given biotech stock.

Taken together, along with a deep understanding of a company's pipeline, they can be extremely helpful in maximizing your profits and minimizing your risk.

Source :http://moneymorning.com/2015/02/20/the-seven-financial-indicators-of-highly-successful-biotech-investors/

Money Morning/The Money Map Report

©2015 Monument Street Publishing. All Rights Reserved. Protected by copyright laws of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), of content from this website, in whole or in part, is strictly prohibited without the express written permission of Monument Street Publishing. 105 West Monument Street, Baltimore MD 21201, Email: customerservice@moneymorning.com

Disclaimer: Nothing published by Money Morning should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investent advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication, or after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended by Money Morning should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.

Money Morning Archive

© 2005-2019 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in